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Background: Self-monitoring of hypertension with self-titration of antihypertensives (self-management) results in
lower systolic blood pressure for at least one year. However, few people in high risk groups have been evaluated to
date and previous work suggests a smaller effect size in these groups. This trial therefore aims to assess the added
value of self-management in high risk groups over and above usual care.
Methods/Design: The targets and self-management for the control of blood pressure in stroke and at risk groups
(TASMIN-SR) trial will be a pragmatic primary care based, unblinded, randomised controlled trial of self-
management of blood pressure (BP) compared to usual care. Eligible patients will have a history of stroke, coronary
heart disease, diabetes or chronic kidney disease and will be recruited from primary care. Participants will be
individually randomised to either usual care or self-management. The primary outcome of the trial will be
difference in office SBP between intervention and control groups at 12 months adjusted for baseline SBP and
covariates. 540 patients will be sufficient to detect a difference in SBP between self-management and usual care of
5 mmHg with 90% power. Secondary outcomes will include self-efficacy, lifestyle behaviours, health-related quality
of life and adverse events. An economic analysis will consider both within trial costs and a model extrapolating the
results thereafter. A qualitative analysis will gain insights into patients’ views, experiences and decision making
processes.
Discussion: The results of the trial will be directly applicable to primary care in the UK. If successful, self-
management of blood pressure in people with stroke and other high risk conditions would be applicable to many
hundreds of thousands of individuals in the UK and beyond.
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The potential benefit from optimal blood pressure (BP)
lowering in patients at high cardiovascular risk following
stroke or TIA, coronary heart disease or with diabetes or
CKD is large. The PROGRESS trial demonstrated that
blood pressure lowering is beneficial in reducing risk of
stroke amongst both hypertensive and non-hypertensive
individuals with a history of stroke or TIA [1,2]. For
people with coronary heart disease, blood pressure low-
ering has the same risk reduction as in those without
coronary heart disease however the higher absolute risk
in CHD means that for a given blood pressure reduction
the absolute benefits are greater [3]. The Hypertension
Optimal Treatment trial showed no difference in outcome
for diastolic blood pressure targets below 90mmHg, apart
from in people with diabetes for whom the 80mmHg tar-
get group did better. The blood pressure trialists collab-
orative have shown similar relative risk reductions from
blood pressure lowering in diabetes compared to other
groups, again with higher absolute risk reductions. In sub-
group analyses of the HOPE study, people with chronic
kidney disease (CKD) received equivalent benefit from
ramipril as those without kidney disease [4].
Guidelines for the various at risk groups vary in terms of
recommendations for blood pressure lowering. The Na-
tional Clinical Guideline for stroke [5] and the British
Hypertension Society (BHS) [6] recommend that unless
there is bilateral carotid artery stenosis, the target blood
pressure for secondary prevention of stroke and TIA
should be 130/80mmHg. NICE guidelines for diabetes,
suggest a lower blood pressure target than recommended
for essential hypertension of 140/80mmHg (130/75mmHg
in cases of proteinuria). For coronary heart disease, stand-
ard blood pressure targets are recommended (≤ 140/90
mmHg), and for chronic kidney disease NICE also recom-
mend a target of 140/90 mmHg, unless there is accom-
panying diabetes or proteinuria (ACR > 70 mg/mmol) in
which case the target drops to 130/80 mmHg. The BHS
guidelines however, suggest a target of <130/80 mmHg for
stroke/ TIA, diabetes, CKD3 (without proteinuria), CHD
and MI allowing uniformity across the range of high risk
groups [6].
Data from national and international surveys suggest
that blood pressure control is sub-optimal [7]. Novel in-
terventions are therefore needed to improve this and as
most blood pressure management is undertaken in pri-
mary care, where hypertension is the commonest long
term condition seen by GPs, it is appropriate that inter-
ventions are delivered in this setting. The TASMINH2
trial [8,9] found that self-management of hypertension
resulted in significantly lower (5.4mmHg) systolic blood
pressure after one year compared to usual care. How-
ever, the study included few people in high risk groups
such as diabetes or CKD, in whom the effect sizeappeared to be smaller and included telemetry which is
not available in daily practice in the NHS.
Self-management can encompass a wide range of be-
haviours in addition to medication titration and moni-
toring of symptoms, such as an individual’s ability to
manage physical, psychosocial and lifestyle behaviours
related to chronic illness [10]. Self-efficacy, which is a
person’s confidence to be able to carry out behaviours to
achieve a desired goal, has been found to be the stron-
gest predictor of a person’s ability to change risky health
behaviours by taking action, and an important character-
istic for successful self-management [11]. It is unclear
what the relationship is between self-monitoring of
blood pressure, self-efficacy and health behaviour modi-
fication; it is possible that the self-monitoring aspect
provides feedback to the individual about their blood
pressure of which they would otherwise be unaware.
This in turn may promote self-management of health
behaviours in those with higher levels of self-efficacy.
These behavioural aspects require further study.
Therefore, the aim of this trial is to determine whether
the benefits from blood pressure lowering observed in
the TASMINH2 trial will also be observed in a popula-
tion of people at high cardiovascular risk without using
telemetry and to assess further the mechanism behind
any change in blood pressure observed. The TASMIN-
SR trial sets out to investigate whether self-management
is effective and cost effective in people with stroke and
other high risk conditions.
Methods/Design
Study aims, research questions, and outcomes
The primary aim of TASMIN-SR is to compare self-
management with usual care in the control of hyperten-
sion in patients with stroke and other at-risk conditions.
The trial has four main research questions:
1. Does self-management of blood pressure result in
better control of blood pressure in people with stroke
and other at-risk conditions compared to usual care?
2. Is self-management of blood pressure in people with
stroke and other at-risk conditions achievable in
routine practice and is it acceptable to patients?
3. What is the relationship between self-management
of blood pressure, self-efficacy, lifestyle behaviours,
patients’ attitude to health and health care and use
of other self-care strategies in people with stroke
and other at-risk conditions?
4. Is self-management of blood pressure in people with
stroke and other at-risk conditions cost effective?
The primary outcome of the trial will be the difference
in office systolic blood pressure (mmHg) at 12-month
follow-up between intervention and control adjusted for
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comes (also adjusted for baseline and co-variates) will
include:
– Difference in office SBP at 6-month follow-up
between intervention and control
– Difference in office DBP at 6 and 12-month follow-
up between intervention and control
– Percentage time in target BP range
– Difference in pulse rate
– Difference in self-management self-efficacy
– Difference in lifestyle behaviours
– Difference in health-related quality of life
– Difference in BP measurement preference
– Difference in anxiety
– Difference in attitudes to health and healthcare
– Difference in use of other self-management
strategies
– Reasons for non-participation
– Adverse events (including cardiovascular events and
death)
– In addition there will be a qualitative analysis and
health economic modelling.
Study design and setting
TASMIN-SR is a pragmatic, primary care based, un-
blinded, randomised controlled trial (with embedded
economic and qualitative analyses) of self-management
of BP consisting of self-monitoring with self-titration of
anti-hypertensive medication in people with stroke and
other at-risk conditions.
Ethical considerations
Ethical approval has been obtained from North West –
Greater Manchester East ethics committee (reference: 10/
H1013/60). Site specific R&D approval will be obtained
from the relevant Primary Care Trusts.
Trial interventions
Usual care will consist of the participant seeing their
General Practitioner (GP) and/or nurse for routine BP
measurement and/or adjustment of medication at the
discretion of the health professional.
Self-management will consist of self-monitoring of BP
with self-titration of medication following a predetermined
3-step plan, dependant on the self-monitored BP readings.
Blood pressure self-monitoring
Participants will be trained to self-monitor BP using an
automated sphygmomanometer. Patients will self-monitor
BP for the first week of each month of the study, and will
take measurements in the morning. Two seated BP read-
ings will be taken, with a five-minute rest period between
them. The second of these readings will be used todetermine if medication requires altering. Participants will
be provided with a guideline that contains simple colour
coded instructions. Very high or very low readings that
persist when a third reading is taken five minutes after the
second reading will require the participant to contact their
practice for advice and potentially will need checking.
Four or more above target readings in two consecutive
weeks of measurement will require a change in medica-
tion. Readings within target range will simply require fur-
ther monitoring the following month.Target blood pressure
Blood pressure targets will be based on The British
Hypertension Society guidelines [6] and Joint British So-
cieties Guidelines [12] that suggest that the BP for pa-
tients with stroke/TIA, diabetes (in the absence of
proteinuria), CKD, CHD, and MI should be <130/80
mmHg. The BHS suggest that for home monitoring this
target should be adjusted by 10/5 mmHg, resulting in a
target of <120/75 mmHg [6].Communication of home readings
Participants will complete a simple form each month to
record their daily BP readings and colour coding. These
forms will be used to determine any action that is re-
quired at the end of the measurement week, including
whether a medication change is required. The form will
be printed on three-part non-carbon copy paper to allow
one copy to be kept by the patient, one returned to the
research team, and one posted to the GP should a medi-
cation change be required. Reply paid envelopes will be
provided for this purpose. At follow-up, data from par-
ticipants’ BP machines will be uploaded onto a database
so that the research team has an electronic copy.Self-titration of medication
Each intervention patient will be given an individually tai-
lored three-step management plan through which to ad-
just medication according to measured BP. Each step will
represent a single medication change (additional medica-
tion or increased dose) that will be made following two
consecutive months of raised readings. Medication choice
will remain at the discretion of the GP who will be pro-
vided with an algorithm summarising the national clinical
guidelines for advice on hypertension. If patients use all
three steps of their management plan they will return to
their GP and an additional two-step plan will be devised.
This will not be until at least eight months into the trial,
assuming no very high or very low readings, so a three-
step plan should be sufficient. Any additional monitoring
(for instance blood tests or urinalysis) will be the responsi-
bility, and at the discretion, of the GP.
Table 1 Data collection throughout the trial
Baseline only:
1 Demographic questions: including age, race, marital status,
occupation, and education
2 Duration of hypertension
3 Past medical history
4 Contraindications to anti-hypertensives
5 Short orientation memory test [15]
6 Height
7 Joint pain questionnaire [16]
Baseline and follow-up:
1 New medical history (in last 6/12 months)
2 Blood pressure (sitting plus standing at baseline)
3 Current anti-hypertensive medications
4 Weight
5 Symptom section of the IPQ [17]
6 Partners in health scale [18]
7 Short-form of the State-Trait Anxiety Inventory [19]
8 EQ-5D [20]
9 Use of complementary and alternative medicine and self-tests [21]
10 BP measurement preference
11 Attitudes to health and healthcare [22]
Lifestyle diaries
1 Simple lifestyle indicator questionnaire (SLIQ) [23]
2 The dietary quality score [24]
3 Self-efficacy (adapted diabetes self-efficacy scale) [25]
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Included with the letter of invitation to take part in the
trial, will be a form for people to voluntarily return
should they wish to decline the invitation. This will ask
for basic demographic details as well as their reasons for
wishing to decline.
Study population
The study population will comprise people with stroke/
TIA, diabetes, CKD3, CABG, MI or angina, with poorly
controlled hypertension managed in primary care. Eligi-
bility criteria will be age above 35, have had a diagnosis
of stroke/TIA, diabetes, CKD3, MI, angina, or CABG,
and clinic blood pressure greater than 130/80. Exclusion
criteria will be inability to self-monitor (such as demen-
tia or score of >10 on the short orientation memory
concentration test), postural hypotension (systolic BP
drop > 20 mmHg), prescribed more than three anti-
hypertensive medications, taking part in a current BP
study or previously having taken part in TASMINH2
[8], terminal disease, pregnant, BP not managed by GP,
and acute cardiovascular event in the previous three
months.
Eligible patients will be identified from general prac-
tices via the UK Primary Care Research Network.
Trained practice nurses will identify potentially eligible
patients by searching practice-based registers for pa-
tients having a Read Code of stroke/TIA, diabetes,
CKD3, Angina, CABG, or MI and whose last systolic BP
measurement was greater than 145 mmHg (BP readings
are often lower when measured by research teams, so a
higher BP at invitation increases the likelihood of BP
readings falling within the suitable range [13].) GPs will
be asked to check the generated lists and remove pa-
tients who have a terminal illness, are pregnant, or who
are thought to be unsuitable for the study.
Participants who withdraw will not be replaced, but
asked if they are prepared to continue to attend follow-
up clinics.
Randomisation
Patients will be randomised to either usual care or self-
management using an internet based system with tele-
phone backup. Minimisation will be used to take into
account practice, gender, age, high risk group (CVD,
diabetes, CKD3, CHD) and baseline BP.
Study clinics and flow through study
At baseline, all patients will attend a clinic at which the
study will be explained, informed consent gained, height,
weight, and BP measurements taken, and questionnaires
regarding demographics, past medical history, BP meas-
urement method preference, use of self-management
strategies, attitudes to health and healthcare completed,and baseline economic data collected (Table 1). Measure-
ment of blood pressure will use a validated automated
electronic sphygmomanometer (BP TRU BPM 200; BP
TRU Medical Devices; Coquitlam, BC, Canada) [14]. After
five minutes of rest, six seated blood pressure readings will
be taken at 1-minute intervals, of which the mean of the
2nd and 3rd reading will comprise the primary outcome.
Patients will then be randomised to either usual care or
self-management. All patients will be given a diary to as-
sess daily lifestyle behaviours and self-management self-
efficacy which they will be asked to complete everyday for
one week starting the first Monday of the month after
their baseline appointment. Patients randomised to usual
care will be asked to book an appointment for a routine
blood pressure check and medication review with the
study GP. Patients randomised to self-management will be
asked to make an appointment with the research team for
a training session on how to monitor their BP. Participants
will be asked to practice at home for a week before
returning for a second training session covering the self-
titration aspect of the intervention. If necessary, a third
training session will be offered for additional support. Fol-
lowing successful completion of the training, patients will
Practice clinical system searches for potentially eligible participants:
Age >35
Hypertension
Diagnosis of stroke/TIA, diabetes, CKD3, MI, angina, and/or CABG
Last systolic BP measurement greater than 145 mmHg
Antihypertensive treatment (  3 antihypertensive medications)
GPs check patient list for personal knowledge of
people likely to be unsuitable:
Terminally ill, pregnant, likely to be unable to
self  manage, otherwise unsuitable
Baseline Clinic: Explanation of study, baseline
data collection and randomisation
Intervention group
two training sessions
Control group
Medication review with
GP
Self  management plan
agreed
Medication review with
GP
Usual CareSelf monitor for one week
each month
Self titrate medication
according to agreed plan
Week 1
Intervention vs
control
Study End
Points
Primary Care
follow up
Follow up with GP
dependent on self
management algorithm
Follow up as decided
by GP
6 and 12 month follow up
plus economic data
collection
6 and 12 month follow up
plus economic data
collection
Figure 1 Flow through the trial.
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their practice for a routine BP check and to devise a three
step titration plan for any potential medication changes.
Patients who are unable to complete all aspects of the
training will be given the option to self-monitor without
self-titration of medications.
Patients will be asked to attend two follow-up clinics at
6- and 12-months post-randomisation. Each clinic will be
timetabled for no more than one hour, during which pa-
tients will have their BP and weight measured by the re-
search team and will be asked to complete a questionnairesimilar to the one completed at baseline. At the 12 month
follow up, participants will also be given a blank postcard
and asked to write a few sentences about their experience
of the trial. Additionally, the research team will check that
patients in the intervention arm are using the blood
pressure monitors correctly. Flow through the trial is
summarised in Figure 1.
Sample size considerations
A sample size of 243 people per group is required for
90% power assuming a standard deviation of 17 mmHg
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tion and control groups. This represents a clinically sig-
nificant decrease in BP and is in line with the reduction
observed in TASMINH2 and would result in around
20% reduction in stroke risk and 10% coronary heart dis-
ease risk. Based on the follow-up in TASMINH and
TASMINH2 self-monitoring trials, a 10% drop out rate
during follow-up is assumed, meaning a sample of 270
per group will need to be randomised, a total of 540 pa-
tients altogether. Should the drop-out rate be higher
than TASMINH2, for instance 20%, the study would
have more than 85% power.
Recruitment
Patients will be recruited over an eight month period.
Based on practice-based pilot searches, it is estimated
that in a practice with an average size of 6000 patients,
2.5% will be eligible for invitation. Previous experience
from the TASMINH2 trial suggests that approximately
30% of invited patients will attend baseline clinics, and
of these 50% will be eligible [8]. A minimum of 25 prac-
tices will be needed in order to recruit the required
number of participants (approximately 22 patients per
practice being randomised) but many more will be avail-
able if necessary.
Statistical analysis
The primary analysis will include all available partici-
pants, i.e. all of those with complete data from follow-up,
and will be performed at the end of the trial after all data
has been collected. A mixed model analysis will be used
to examine differences between intervention and control
systolic BP at twelve months, adjusting for practice (as a
random effect), baseline BP, gender, and high risk group.
Planned sub group analyses will be of older vs younger
(65 as threshold), males vs females, better controlled at
baseline vs worse controlled at baseline (threshold 145
systolic), the different risk groups and deprivation. Sensi-
tivity analyses will examine the potential effect of missing
data. These will include multiple imputation, replace-
ment of missing data by the most recent previous data
or by the mean of the series. Any deviation from the ori-
ginal statistical plan will be described in the final report
and publications.
Economic analysis
The economic analysis will be in two parts. The first part
is a cost-effectiveness analysis conducted alongside the
randomised clinical trial (trial-based analysis). An eco-
nomic evaluation will compare the strategy of self-
management of blood pressure in at-risk patients to the
strategy of usual care. Primary outcome will be expressed
in terms of the cost per additional 1 mm Hg reduction in
office SBP from baseline to 12 months. Use of utility-based outcomes (EQ-5D) will allow a secondary outcome
to be the cost per quality-adjusted life year (QALY) gained
over the same 12 months period. The results for both
outcomes will be expressed in terms of incremental cost-
effectiveness ratios (ICERs). NHS resource use will include
hospital and GP consultations, medications, referrals,
equipment and training. Intervention costs, including
equipment and training, will be collected by the research
team. All other resource use data will be collected from
practice computer systems by the research team at follow
up visits. Cost data will be derived from sources such as
the British National Formulary (BNF), the National Sched-
ule for Reference Costs and the Unit Costs of Health and
Social Care (PSSRU) [26].
The second part will be a model-based cost-effectiveness
analysis, building on the trial-based analysis and using pub-
lished data on long-term outcomes and costs. The model
will estimate the long-term cost-effectiveness of self-
management of blood pressure in people with stroke and
other at- risk conditions in terms of cost per QALY gained.
The model type and structure will be informed by
reviewing modelling studies which consider outcomes after
stroke and other at-risk conditions. Experts within the
team will advise on the final structure of the model. Costs
to be included in the model will be for self-management
(from the trial based analysis), hospital stays, readmissions
and long-term care for stroke and other cardiovascular
outcomes related to level of disability and discharge destin-
ation. Resource use will be determined from the trial and
estimates from the literature. Unit costs will be collected
from published sources (National Schedule for Reference
Costs and the PSSRU) [26]. Outcomes will be in the form
of survival and quality of life and will use data collected
from the trial and literature on quality of life after stroke.
The model will be run over remaining patient lifetime, with
costs and benefits discounted at a rate of 3.5%. The analysis
will be conducted from an NHS perspective. Extensive de-
terministic sensitivity analysis will be undertaken to assess
the impact of changing the values of key parameters. For
each important model parameter, we will determine a
point estimate and construct a probability distribution
around that estimate. Probabilistic sensitivity analyses will
be conducted to deal with uncertainty in model parameters
and cost-acceptability curves presented.
Qualitative sub study
This part of the study aims to gain insight into patients’
decision making processes regarding whether to seek
professional advice, whether to make a medication
change, or any concerns they may have.
Open comments
Each month, on an open-comment section of the BP
measurement record, intervention patients will be asked
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whether it followed protocol or not, their decision mak-
ing process, and their thoughts and feelings associated
with the decision making. Similarly, the postcards partic-
ipants will be given at the end of the study provide a fur-
ther opportunity for open comment about the trial. This
approach is useful for capturing aspects of a patient’s ex-
perience of a study or an intervention which may other-
wise not be documented [27]. The open comments will
be analysed by content analysis using both quantitative
(e.g. number of times a word/phrase mentioned) and
qualitative (e.g. examples of participants’ own words to
reflect emerging themes) techniques. Concepts identified
will be integrated into themes providing a structure for
presentation of findings.
Discussion
The results of the trial will be directly applicable to pri-
mary care in the UK. If successful, self-management of
blood pressure in people with stroke and other high risk
conditions would be applicable to many hundreds of
thousands of individuals in the UK and beyond.
It is anticipated that the potential risks of this study
are low and similar to those associated with usual care.
Particular issues are potential increased anxiety when
patients find excessively high or low blood pressure
readings, or as a result of self-titration. The patient
guideline will advise contact with the supervising phys-
ician or nurse for a blood pressure check and further
management if required. Training of participants will
cover repeated measurements in the case of high or low
readings and a helpline will be available should partici-
pants or clinical staff require advice over and above that
provided in the guideline. The study GP will have con-
trol over prescription of all medications within the study,
and will make changes to prescriptions as required. Par-
ticipants will be advised to attend their GPs should they
experience an adverse event thought to be due to their
participation in the trial.
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Article summary
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